证券代码：688163 证券简称：赛伦生物 公告编号：2024-024 上海赛伦生物技术股份有限公司 2024 年半年度权益 分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2024/9/11 | 2024/9/12 | 2024/9/12 | 一、 通过分配方案的股东大会届次和日期 公司 2024 年 5 月 20 日的 2023 年年度股东大会已审议通过关于提请股东大会 授权董事会进行 2024 年度中期分红的议案，本次利润分配方案经 2024 年 8 月 27 日召开的第三届董事会第二十一次会议审议通过。 1. 发放年度：2024 年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 是否涉及差异化分红送转：否 每股分配比例 每股现金红利 0.12 元 相关日期 3. 分配 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2024-021 上海赛伦生物技术股份有限公司 第三届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会的召开情况 上海赛伦生物技术股份有限公司（以下简称"公司"）第三届监事会第十六 次会议（以下简称"本次会议"）于 2024 年 8 月 27 日以现场结合通讯方式召开， 本次会议通知及相关材料已于 2024 年 8 月 15 日以电子邮件的方式送达公司全 体监事。公司监事 3 人，实际出席监事 3 人。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规、规范性文件和《公司章程》《监事会议事规则》的有关规定，会议形成的决 议合法、有效。 二、 监事会会议审议情况 经与会监事投票表决，审议通过了如下议案： 1、审议通过《关于公司 2024 年半年度报告及摘要的议案》 监事会认为： （1）2024 年半年度报告及其摘要的编制和审议程序符合相关法律、法规、 规范性文件、《公司章程》和公司内部管理制度的要求； （2）20 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥98,058,273.88, representing a 4.58% increase compared to ¥93,759,588.31 in the same period last year[17]. - Net profit attributable to shareholders increased by 20.06% to ¥32,307,812.26 from ¥26,909,324.11 year-on-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 24.12% to ¥22,807,500.95 compared to ¥18,374,922.05 in the previous year[20]. - The net cash flow from operating activities improved by ¥15,842,200.50, moving from -¥18,887,952.07 to -¥3,045,200.43 year-on-year[20]. - As of the end of the reporting period, the net assets attributable to shareholders increased by 0.98% to ¥1,096,504,417.73 from ¥1,085,840,605.47 at the end of the previous year[20]. - Total assets increased by 0.28% to ¥1,131,634,861.69 from ¥1,128,472,545.63 year-on-year[20]. - Basic earnings per share rose to ¥0.30, a 20.00% increase from ¥0.25 in the same period last year[18]. - The company achieved a revenue of 98.06 million RMB in the first half of 2024, representing a year-on-year growth of 4.58%[58]. - The net profit attributable to shareholders reached 32.31 million RMB, with a year-on-year increase of 20.06%[58]. - The net profit after deducting non-recurring gains and losses was 22.81 million RMB, up 24.12% year-on-year[58]. Research and Development - The R&D investment as a percentage of operating revenue increased to 12.64%, up by 3.04 percentage points from 9.60% year-on-year[18]. - The company reported a total R&D investment of ¥12,398,153.48, representing a 37.72% increase compared to ¥9,002,649.30 in the same period last year[46]. - The company received ethical review approval for the Phase II clinical trial of the anti-viper snake venom serum project in January 2024, with the trial kickoff meeting held in May[44]. - The company developed a rapid diagnostic reagent for cobra venom, receiving ethical review approval in March 2024 and completing clinical trial registration in April[44]. - The company has obtained two invention patents during the reporting period, bringing the total number of granted patents to 14 out of 29 applications[45]. - The company has established a core proprietary technology for the preparation of safe, effective, and stable emergency treatment drugs, continuously optimizing and innovating through large-scale production applications[37]. - The company has developed high-efficiency virus inactivation technology to ensure product safety and reduce contamination risks from pathogenic viruses[41]. - The company has implemented a single plasma collection and blood return technology to ensure the health of horses while increasing plasma yield[40]. - The company’s antigen purification technology enhances the efficacy of immunization schemes by ensuring high purity and activity of antigens[38]. - The company has optimized the pepsin digestion process, improving the quality of each batch of antiserum/immune globulin produced[42]. Product and Market Information - The company operates in the pharmaceutical manufacturing industry, specifically in the biopharmaceutical sector focusing on antiserum and antitoxin products[22]. - The company is a leading biopharmaceutical enterprise specializing in antivenom and antitoxin products, with a comprehensive competitive edge in research, development, production, and sales[25]. - The main products include antivenom for various snake species and tetanus immunoglobulin, with antivenom being the only effective treatment for snake bites in China[26][27]. - The company has achieved fourth-generation production standards for its main products, including tetanus immunoglobulin and antivenom, aligning with advanced international practices[24]. - The company is actively expanding its product line, with ongoing clinical research for new products such as antivenom for pit vipers and rapid diagnostic kits for snake venom[26]. - The antivenom products are listed in the National Essential Medicines List and the National Medical Insurance Directory, indicating their importance in public health[28]. - The company emphasizes the critical timing and dosage of antivenom administration to effectively prevent further damage from snake venom, highlighting the importance of early intervention[28]. - The company’s tetanus immunoglobulin is classified as a passive immunization agent and is included in the National Medical Insurance Directory[30]. - The rabies serum is designed for immediate neutralization of the rabies virus, providing protection during the high-risk period before the vaccine takes effect[31][32]. - The company holds a leading position in the domestic market for anti-venom products, including unique products like anti-cobra venom serum and anti-tetanus immunoglobulin[53]. Corporate Governance and Compliance - The report period covers January 1, 2024, to June 30, 2024, and the financial report is unaudited[4][11]. - The board of directors has ensured that the semi-annual report is truthful, accurate, and complete, with no significant omissions[2][8]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[7]. - There are no special arrangements for corporate governance or significant matters reported[8]. - The company has not violated decision-making procedures for external guarantees[7]. - The company has not proposed any stock dividends or capital reserve transfers in the current profit distribution plan[5]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a substantive commitment to investors[6]. - The company has maintained compliance with all promised commitments related to shareholding and management[99]. - There are no updates on environmental information disclosures or measures taken to reduce carbon emissions[97]. - The company has not reported any changes in user data or performance metrics during the reporting period[97]. Risk Factors - The company has described potential risks in the "Management Discussion and Analysis" section, urging investors to be cautious of investment risks[3]. - The company faces risks related to core technology leakage, which could lead to a decline in market position for its unique products[61]. - The company’s main products, including antivenom serum and tetanus immunoglobulin, are facing potential price control and competition risks, which could impact revenue growth[63]. - The company’s product structure is relatively single, relying heavily on antivenom serum and tetanus immunoglobulin, posing risks if sales decline[67]. - The company is at risk of market competition intensifying, particularly for its tetanus immunoglobulin product, which may affect pricing and market share[64]. - The company’s products are included in national essential drug lists, but future adjustments could negatively impact operations if products are removed[69]. - The company is enhancing its market promotion efforts for its main products, but risks exist if promotional activities do not meet expectations[68]. - The company benefits from a 15% corporate income tax rate as a high-tech enterprise, but changes in tax policies could adversely affect its financial performance[73]. Shareholder and Dividend Policy - The company plans to distribute a cash dividend of RMB 1.20 per 10 shares, totaling RMB 12,986,400, which represents 40.20% of the net profit attributable to shareholders for the first half of 2024[5]. - The company has committed to a 36-month lock-up period for major shareholders following the IPO, which began on February 18, 2022[98]. - All major shareholders have adhered to their commitments regarding share transfer restrictions during the lock-up period[99]. - The company has a long-term commitment to not transfer shares held prior to the IPO, ensuring stability in ownership[101]. - The company aims to ensure stable and continuous dividend returns, potentially increasing the distribution ratio and frequency[125]. - The board must complete the distribution of dividends within two months after the shareholders' meeting approval[127]. - The company can propose stock dividends if it believes that the stock price does not match the capital scale, while ensuring sufficient cash dividends[127]. - The company commits to initiating a share repurchase program within 5 working days if any false statements or significant omissions are identified by regulatory authorities that materially affect the company's compliance with issuance conditions[130]. - The funding for the repurchase will primarily come from the company's own funds, with commitments from controlling shareholders to provide necessary financial support if needed[130]. - The company will strictly adhere to relevant laws and regulations during the repurchase process and ensure timely and smooth completion of the repurchase[130]. Environmental and Social Responsibility - The company invested 692,600 RMB in environmental protection during the reporting period[90]. - The company has established pollution control facilities, including ammonium sulfate recovery and activated carbon purification systems, ensuring compliance with environmental regulations[92]. - The company has a valid pollution discharge permit for its factory expansion project, effective until January 6, 2027[93]. - The company has implemented an emergency response plan for environmental incidents, updated in 2023, to enhance crisis management capabilities[94]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[96]. - The company’s waste management includes regular collection of hazardous waste by qualified units and treatment of general industrial solid waste[91]. - The company’s environmental monitoring plan for 2024 includes standards for air, water, noise, soil, and groundwater, with regular assessments by qualified entities[95]. Fundraising and Investment - The total amount used for stock buybacks cannot exceed 50% of the previous year's net profit attributable to shareholders[116]. - The company has approved the use of up to RMB 630,000,000 of idle raised funds for cash management, with a balance of RMB 590,000.00 at the end of the reporting period[148]. - The total amount of raised funds is RMB 384,923,575.78, with RMB 115,000,000.00 utilized, representing a utilization rate of 29.88%[146]. - The company has fully utilized ¥115,000,000 for permanent working capital, achieving 100% of the planned investment[144]. - The company has established a fundraising management system to ensure the safe use of raised funds and to prevent risks associated with fund usage[119]. - The company aims to accelerate the investment progress of fundraising projects to expand overall business scale and capacity, striving for early production and expected returns[119]. Management and Governance Changes - The company appointed Peng Liangjun as the new deputy general manager and core technical personnel, while He Yiming resigned from the deputy general manager position but remains a board member and technical advisor[86]. - The company has established a clear plan for gradual share reduction after the lock-up period, considering market stability and operational needs[111]. - The management team is committed to timely reporting of any changes in shareholdings during their tenure[109]. - The management team has agreed to maintain their commitments regardless of any changes in their positions within the company[109].

证券代码：688163 证券简称：赛伦生物 公告编号：2024-023 上海赛伦生物技术股份有限公司 关于 2024 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2024年半年度每股分配比例：每10股派发现金红利1.20元（含税），不送 红股，不以资本公积金转增股本。 2024年半年度利润分配以实施权益分派股权登记日登记的总股数为基数， 具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配总 额不变，相应调整每股分红比例，并将另行公告具体调整情况。 一、2024 年半年度利润分配方案内容 公 司 2024 年 半 年 度 实 现 归 属 于 上 市 公 司 股 东 的 净 利 润 为 人 民 币 32,307,812.26 元，母公司实现的净利润为人民币 34,505,476.39 元；截至 2024 年 6 月 30 日，母公司可供分配利润为人民币 58,716,257.40 元。公司 2024 年半年 度拟以实施权益分派股权登 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2024-022 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司 首次公开发行股票注册的批复》（证监许可【2022】204 号）的批准，公司获准 向社会公开发行人民币普通股 2,706 万股，每股面值为 1.00 元，每股发行价格 为 33.03 元，公司收到募集资金总额为 89,379.18 万元，扣除发行费用 10,886.82 万元，募集资金净额为 78,492.36 万元。上述募集资金已于 2022 年 3 月 4 日全部 到位，并存放于募集资金专项账户内。天职国际会计师事务所（特殊普通合伙） 于 2022 年 3 月 4 日出具了《验资报告》（天职业字【2022】9819 号）。 上海赛伦生物技术股份有限公司 截至 2024 年 6 月 30 日，公司累计使用募集资金 197,471,613.82 元，募集资 金余额为 634,711,189.49 元。报告期内，公司募集资金使用及余额情况如下： 2024 年半年度募集资金存放与实际使用情况的专项报告 | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2024-020 上海赛伦生物技术股份有限公司 关于实际控制人之一、董事、总经理及部分高级管理人员 增持股份计划实施完毕暨增持结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 增持计划的基本情况：上海赛伦生物技术股份有限公司（以下简称"公 司"）实际控制人之一、董事、总经理范铁炯先生，及副总经理、董事会秘书成 琼女士，副总经理彭良俊先生，财务总监李绍阳先生（以下简称"增持主体"） 基于对公司未来发展的信心和对公司长期投资价值的认可，同时为增强投资者信 心，维护公司全体股东利益，计划自 2024 年 2 月 26 日起 6 个月内，通过上海证 券交易所系统允许的方式（包括但不限于集中竞价和大宗交易等）增持公司股份， 合计增持金额不低于人民币 380 万元，且不超过人民币 630 万元。具体内容详见 公司 2024 年 2 月 24 日于上海证券交易所网站（www.sse.com.cn）披露的《关于 实际控制人之一、董事、总经理及部分高级管理人员增 ...

法律意见书 邮编：200120 上海市锦天城律师事务所 法律意见书 实际控制人之一、董事、总经理及部分高级管理人员 增持公司股份的 上海市锦天城律师事务所 关于上海赛伦生物技术股份有限公司 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 上海市锦天城律师事务所 电话：021-20511000 传真：021-20511999 关于上海赛伦生物技术股份有限公司 致：上海赛伦生物技术股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海赛伦生物技术 股份有限公司（以下简称"赛伦生物"或"公司"）的委托，根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司收购管理办法》（以下简称"《收 购管理办法》"）等法律、法规、规章和规范性文件的相关规定，就公司实际 控制人之一、董事、总经理范铁炯先生，副总经理、董事会秘书成琼女士，副总 经理彭良俊先生及财务总监李绍阳先生（以下合称"增持人"）增持公司股份 的有关事宜（以下简称"本次增持"），出具本法律意见书。 声明事项 一、本所及本所律师对本法律意见书所涉及的有关事实的了解 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2024-019 上海赛伦生物技术股份有限公司 公司董事会、监事会延期换届不会影响公司的正常运营。公司将积极推进相 关工作，尽快完成董事会与监事会的换届选举工作并及时履行信息披露义务。 特此公告。 上海赛伦生物技术股份有限公司 董事会、监事会 关于董事会、监事会延期换届的提示性公告 本公司董事会、监事会及全体董事、监事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担 法律责任。 上海赛伦生物技术股份有限公司（以下简称"公司"）第三届董事会及监事 会任期将于 2024 年 8 月 23 日届满。鉴于公司新一届董事会、监事会的候选人提 名工作尚在进行中，同时考虑到 2024 年半年度报告编制及审议等工作事项，为 保证公司董事会、监事会及半年度报告等相关工作的连续性、稳定性，公司董事 会及监事会换届工作将适当延期进行，同时董事会各专门委员会、高级管理人员 的任期亦相应顺延。 在换届选举工作完成前，公司第三届董事会、第三届监事会全体成员、董事 会各专门委员会成员及高级管理人员将依照相关法律法规和《公司章程》等有 ...

上海赛伦生物技术股份有限公司 证券代码：688163 证券简称：赛伦生物 公告编号：2024-018 暨落实"提质增效重回报"行动方案的公告 1 关于收到实际控制人之一、董事长 2024 年度中期分红提议 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海赛伦生物技术股份有限公司（以下简称"公司"）于 2024 年 7 月 16 日 收到公司实际控制人之一、董事长范志和先生出具的《关于提议上海赛伦生物技 术股份有限公司实施 2024 年度中期分红的函》，现将相关情况公告如下： 一、提议情况 为提升上市公司投资价值，与投资者共享发展成果，增强投资者获得感，推 动公司"提质增效重回报"，公司实际控制人之一、董事长范志和先生提议公司 董事会根据股东大会决议，在符合利润分配的条件下制定并实施 2024 年度中期 分红方案，建议分红金额不低于 2024 年上半年归属于上市公司股东净利润的 30%。 范志和先生承诺其与一致行动人、公司董事、总经理范铁炯先生将在公司董 事会审议该等事项时投"赞成"票。 二、其他说明 1、股东大会授权董 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2024-017 上海赛伦生物技术股份有限公司 2023 年年度权益 分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2024/5/31 | 2024/6/3 | 2024/6/3 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2024 年 5 月 20 日的 2023 年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本 108,220,000 股为基数，每股派发现 金红利 0.2 元（含税），共计派发现金红利 21,644,000.00 元。 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | -- ...